header logo image


Page 36«..1020..35363738..5060..»

Archive for the ‘Diabetes’ Category

Number of people in Turkey with diabetes rising: expert – Anadolu Agency

Tuesday, December 17th, 2019

ANTALYA, Turkey

More people in Turkey are being diagnosed with diabetes compared with previous years, an expert said Sunday.

Speaking to the media, Tugbay Tug, a professor at Ankara Universitys Faculty of Medicine, Department of General Surgery, said the number of people in Turkey with diabetes now accounts for more than 10% of the population compared with 7% five years ago.

Tug underlined that Turkey is the third highest country in Europe in terms of the number of diabetes patients.

About half of the patients with diabetes are losing their feet because of foot wounds, he said.

The mortality rate of patients who have lost one organ is much higher than the mortality rate caused by most lethal cancers, and 50% die within three years, he added.

Tug warned that diabetes should not be ignored.

One out of 10 people in society are diabetes patients and the number of people with diabetes totals more than 8 million in Turkey, he added.

He said 20% of Turkeys population will have diabetes by 2025 if people dont change their dietary habits.

Scientific data shows that one in four diabetes patients suffer foot wounds. We can say that there are at least 2 million diabetic foot patients in Turkey. This number will increase if we dont live healthy.

*Writing by Davut Demircan

View post:
Number of people in Turkey with diabetes rising: expert - Anadolu Agency

Read More...

More Bexar County Youth Are Being Diagnosed With Type 2 Diabetes, Prediabetes – Texas Public Radio

Thursday, December 12th, 2019

THURSDAY at noon on "The Source" An estimated14%of Bexar County's population lives with Type 2 diabetes. This preventable disease typically presents later in life, but is increasingly contracted by youn peoplewho can experience earlier, more advanced complications such as blindness, amputations and even death.

Of the more than30 millionAmerican adults with diabetes, approximately90%live with Type 2, which is managed with diet, exercise and insulin.Approximately half a million Texans are still undiagnosed.

Risk factors include poor diet, obesity, sedentary lifestyle and prediabetes. Children diagnosed with Type 2 diabetes often have a family history with the disease.

According to the Centers for Disease Control and Prevention, nearly 1 in 5 adolescents are living with prediabetes, defined as having blood sugar levels higher than normal but not yet at the threshold for an official Type 2 diabetes diagnosis.

Is there a public health strategy to combat the epidemic of Type 2 diabetes in Bexar County? Who is most at risk and what's being done to break the cycle?

What are the potential short and long term effects of Type 2 diabetes? Can it be reversed with healthier living? What does responsible treatment entail and how do individuals without health insurance manage?

What is to blame for the rising rates of Type 2 and prediabetes in young people? Could earlier identification and treatment help mitigate the disease?

The Texas Diabetes Institute is recruiting for diabetes-related clinical trials. Interested listeners can call 210-358-7200 for more information.

Guests:

"The Source" is a live call-in program airing Mondays through Thursdays from 12-1 p.m. Leave a message before the program at (210) 615-8982. During the live show, call 210-614-8980, email thesource@tpr.org or tweet @TPRSource.

*Audio for this interview will be available by 3:30 p.m. on Thursday, December 12.

Excerpt from:
More Bexar County Youth Are Being Diagnosed With Type 2 Diabetes, Prediabetes - Texas Public Radio

Read More...

Maternal diabetes in pregnancy tied to heart disease in adult kids – Reuters

Thursday, December 12th, 2019

(Reuters Health) - People whose mothers had diabetes during pregnancy may be at increased risk of developing cardiovascular disease by early adulthood, a recent study suggests.

The analysis followed more than 2.4 million babies born in Denmark for up to four decades, including nearly 55,000 whose mothers had diabetes during pregnancy. During the study period, cardiovascular disease developed before age 40 in 1,153 people whose mothers had diabetes while pregnant and 91,311 whose mothers did not.

When mothers had diabetes during pregnancy, their offspring were 29% more likely to develop cardiovascular disease, researchers report in The BMJ.

Preventing, screening and treating diabetes in women of childbearing age may be important not only for improving health of the women but also for reducing long-term cardiovascular disease risks in their offspring, said study leader Yongfu Yu of Aarhus University in Denmark.

We also need to monitor cardiovascular disease risks in offspring of diabetic mothers and investigate possible life-course interventions that may reduce the occurrence of cardiovascular disease, Yu said by email.

A total of 26,272 infants were born to mothers who had gestational diabetes, which develops during pregnancy and usually disappears after the pregnancy is over.

Another 22,055 babies were exposed to their mothers type 1 diabetes, which typically develops in childhood or young adulthood when the pancreas cant produce insulin.

And 6,537 infants were exposed to maternal type 2 diabetes, which is linked to overweight and aging and happens when the body cant properly use insulin to convert blood sugar into energy.

Gestational diabetes was associated with a 19% higher risk of cardiovascular disease in early adulthood for the children, while exposure to maternal type 1 or type 2 diabetes was tied to a 34% greater risk of cardiovascular disease for the young adult children.

The study wasnt designed to determine whether maternal diabetes causes cardiovascular disease or hastens its development in offspring.

The children exposed in utero to maternal diabetes were also more likely to have parents with a history of cardiovascular disease, and to have higher rates as adults of obesity, high blood pressure, high cholesterol, chronic kidney disease - and diabetes, which is itself a powerful risk factor for heart disease.

Yu noted that pregnant women with diabetes have more glucose, or sugars, in the placenta, which may lead developing babies to produce more insulin and have higher levels of blood sugar while theyre in the womb. That, in turn, could potentially lead to changes in blood vessel function later in life that contribute to cardiovascular disease.

We have known for a while that children born to women with diabetes, including both diabetes before pregnancy as well as gestational diabetes, have a higher rate of important complications early in life including macrosomia (babies that are too large sometimes resulting in difficult deliveries), a higher rate of congenital malformations, more frequent admission to NICU because of babies having difficulties regulating their own blood sugar levels, to name a few, said Dr. Jorge Chavarro of the Harvard T.H. Chan School of Public Health in Boston.

These babies are known to have higher risks for being overweight or obese in childhood, and recent work has also suggested theyre at higher risk of cardiovascular and metabolic diseases as adults based on risk factors like levels of sugar and fats in the blood, said Chavarro, who wasnt involved in the study. This new study, he said by email, provides evidence that maternal diabetes can also result in a higher frequency of clinically relevant cardiovascular events during the first four decades of life.

SOURCE: bit.ly/2PBOV8h The BMJ, online December 4, 2019.

The rest is here:
Maternal diabetes in pregnancy tied to heart disease in adult kids - Reuters

Read More...

Resolve to take charge of diabetes – The Daily Advocate

Thursday, December 12th, 2019

GREENVILLE A new year is a great time to learn how to improve your health by increments with a free six-week Healthy U workshop for adults living with diabetes or pre-diabetes 2-4:30 p.m. on Fridays, January 10 through February 14 at Family Health (Conference Room), 5735 Meeker Road, Greenville. The workshop is open to adults of any age living with diabetes, pre-diabetes, and/or their caregivers.

Workshops need a minimum number of participants in order to take place. Register by calling Jane Urlage at (937) 547-2319, ext. 1229 or emailing jurlage@familyhealthservices.org. Sign up now to celebrate a healthier Valentines Day.

Healthy U is an evidence-based, interactive, small group workshop proven to improve quality of life and reduce health care expenses by increasing self-confidence and providing new skills to better manage symptoms and feel healthier. Participants explore new ways to address challenges common to anyone with diabetes. This workshop is different from clinical diabetes programs, and instead focuses on common problems like chronic pain, nutrition, exercise, medication use, emotions, and communicating with doctors and family. Participants develop skills and coping strategies to manage symptoms through setting achievable goals, problem-solving, decision-making, social support, and more.

Everyone who completes the course receives the companion textbook, Living a Healthy Life with Chronic Conditions, and a relaxation CD.

Workshops are supported by the Area Agency on Aging, PSA 2. The Agency on Aging helps older adults of west central Ohio remain in their homes with independence and dignity. We are an independent, private, nonprofit corporation that plans and funds services for older persons in Champaign, Clark, Darke, Greene, Logan, Miami, Montgomery, Preble, and Shelby Counties.

Read more:
Resolve to take charge of diabetes - The Daily Advocate

Read More...

Significant Effect of Diamyd in Type 1 Diabetes Shown in a New Comprehensive Analysis of Previous Phase III and Phase II Trials – PRNewswire

Thursday, December 12th, 2019

STOCKHOLM, Dec. 12, 2019 /PRNewswire/ -- Diamyd Medical announces that a new analysis based on data from more than 530 individual patients from previous phase III and II trials in Europe and US with the diabetes vaccine Diamyd has identified genetically defined subgroups of type 1 diabetes patients that show a positive and statistically significant dose-dependent treatment response.

In the analysis, patients who were positive for certain HLA genotypes and treated with the highest number of doses of Diamyd (three and four subcutaneous injections) experienced a statistically significant treatment effect of approximately 60% compared to placebo at 15 months from baseline. Also, when treatments with low number and high number dose regimens (two, three and four subcutaneous doses) were combined, a statistically significant treatment effect of approximately 40% was seen.

"This has great significance for Diamyd Medical, type 1 diabetes research and the antigen-specific immunotherapy field in general", says Mark Atkinson, Professor and Board member of Diamyd Medical. "These results support the notion that you can identify patients that will have a much higher likelihood to respond to a GAD-based therapy based on a well-known and scientifically plausible genetic profile. This finding has implications for both disease prevention as well as intervention trials in type 1 diabetes. I am encouraged that we are poised to advance a safe, specific and efficious treatment that has the potential to signifcantly change the course of this disease."

"The importance of today's announcement cannot be understated," says Ulf Hannelius, CEO of Diamyd Medical. "This finding strengthens the likelihood of success for the diabetes vaccine Diamyd and will be taken into account in the analysis of the ongoing DIAGNODE-2 trial. Notably, in the phase IIb trial DIAGNODE-2 we are advancing intralymphatic administration of Diamyd which we forsee to be even more efficacious than the subcutaneous route used in previous trials."

Professor Johnny Ludvigsson, Principal Investigator for the analysed Swedish Phase II and European Phase III trials and for the ongoing Phase IIb trial DIAGNODE-2 trial underlines the importance of these findings: "This may be a break through step towards understanding how personalized medicine for autoimmune diseases will evolve. It is a great achievment to for the first time be able to identify a large cohort of patients that experience a significant effect of autoantigen-specific treatment."

The analysis is based on data from more than 530 patients from three previously published trials: a European phase III trial, a Swedish phase II trial and a US phase II trial. The group showing the strongest response to the GAD-specific immunotherapy Diamyd represented approximately 25% of the total number of patients involved in the analysis. Also, a more broadly defined responder subgroup, representing approximately 50% of the total number of patients, showed a statistically significant treatment response. The results will be submitted as an abstract to a scientific conference and are based on a collaborative effort between Diamdy Medical, academic researchers and clinicians.

About Diamyd Medical

Diamyd Medical develops the diabetes vaccine Diamyd, as an antigen-specific immunotherapy for the preservation of endogenous insulin production. Diamyd has demonstrated good safety in trials encompassing more than 1,000 patients as well as effect in some pre-specified subgroups. Besides the Company's own European Phase IIb trial DIAGNODE-2 where the diabetes vaccine is administered directly into a lymph node, two investigator initiated clinical trials are ongoing with Diamyd. Diamyd Medical also develops the GABA-based investigational drug Remygen for regeneration of endogenous insulin production. An investigator-initiated Remygen trial in patients living with type 1 diabetes for more than five years is ongoing at Uppsala University Hospital. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB and has holdings in the medtech company Companion Medical, Inc., San Diego, USA.

Diamyd Medical's B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company's Certified Adviser; phone: +46 8-528 00 399, e-mail: info@fnca.se.

CONTACT:

For further information, please contact: Ulf Hannelius, President and CEOPhone: +46 736 35 42 41E-mail: ulf.hannelius@diamyd.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/diamyd-medical-ab/r/significant-effect-of-diamyd--in-type-1-diabetes-shown-in-a-new-comprehensive-analysis-of-previous-p,c2989690

The following files are available for download:

SOURCE Diamyd Medical AB

Continued here:
Significant Effect of Diamyd in Type 1 Diabetes Shown in a New Comprehensive Analysis of Previous Phase III and Phase II Trials - PRNewswire

Read More...

For sale: Long-acting PhIII GLP-1 diabetes drug that’s way behind rivals, now spurned by Sanofi – Endpoints News

Thursday, December 12th, 2019

Earlier on Monday, new Sanofi CEO Paul Hudson baited the hook on his upcoming strategy presentation Tuesday with a tell-tale deal to buy Synthorx for $2.5 billion. That fits squarely with hints that hes pointing the company to a bigger future in oncology, which also squares with a major industry tilt.

In a big reveal later in the day, though, Hudson offered a slate of stunners on his plans to surgically dissect and reassemble the portfoloio, saying that the company is dropping cardio and diabetes research which covers two of its biggest franchise arenas. Sanofi missed the boat on developing new diabetes drugs, and now its pulling out entirely. As part of the pullback, its dropping efpeglenatide, their once-weekly GLP-1 injection for diabetes.

To be out of cardiovascular and diabetes is not easy for a company like ours with an incredibly proud history, Hudson said on a call with reporters, according to the Wall Street Journal. As tough a choice as that is, were making that choice.

Unlock this story instantly and join 67,500+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

Read this article:
For sale: Long-acting PhIII GLP-1 diabetes drug that's way behind rivals, now spurned by Sanofi - Endpoints News

Read More...

Mothers With Diabetes, Kids With Heart Disease – P&T Community

Thursday, December 12th, 2019

Maternal diabetes before or during pregnancy is associated with increased risks of metabolic syndromeand congenital heart disease in offspring. Research has shown that the children of mothers with elevated blood sugar that is shy of level that would categorize them as havingof gestational diabetes are, nonetheless,more likely to be obese. But less is known about the associations between prenatal exposure to maternal diabetesand early-onset CVD in infants. So researchers from Aarhus University Hospital, Denmark, and University of California, Los Angeles, looked at data from nearly 2.5 million births to find out more. They reported their results on Dec. 4, 2019, on the BMJ website,

During up to 40 years of follow-up, 1,153 offspring of mothers with diabetes were diagnosed with CVD, as were 91,311 children of mothers without diabetes. The offspring of mothers with diabetes had a 29% increased overall rate of early-onset CVD.

Children of mothers with diabetes were also more likely to have diabetes, hypertension, hypercholesterolemia, and chronic kidney diseases, and to be obese. The rates of specific types of CVD were increased for heart failure, and close to doubled for hypertensive disease, deep vein thrombosis, and pulmonary embolism. A mother with diabetes and CVD herself also nearly doubled the offsprings chances of early-onset CVD.

The diabetic intrauterine environment could have a programming effect on the development of CVD in children, the researchers say. They note that during pregnancies complicated by diabetes, large amounts of maternal glucose freely cross the placenta, which could lead to increased secretion of fetal insulin. Exposure to hyperinsulinemia and hyperglycemia could have long-lasting effects, they say, and result in changes in vascular function. Their findings underscore the importance of screening for diabetes risks, especially in pregnant women, to avoid multigenerational hits to heart health.

See the original post here:
Mothers With Diabetes, Kids With Heart Disease - P&T Community

Read More...

The Effect of Diabetes on the Labor Market – DocWire News

Thursday, December 12th, 2019

A study discovered that diabetes may have an adverse impact on the labor market due to work absence, unemployment, and disability pension. Danish national registers were queried to identify patients with type 1 (n=431) and type 2 (n=4,047) diabetes between 1994 and 2011; patients with diabetes were compared with non-diabetic controls (n=101,295). The authors employed multi-state Cox proportional hazards analyses to calculate hazards ratios (HRs) with 95% confidence intervals (CIs) for transitions between work, sickness absence, unemployment, and disability pension. Compared with non-diabetics, those in both diabetes cohorts were significantly more likely to sustain sickness absence (type 1 diabetes women, HR, 1.34; 95% CI, 1.12-1.62; type 1 diabetes men, HR, 1.43; 95% CI, 1.01-2.03 vs. type 2 diabetes women, HR, 1.46; 95% CI, 1.35-1.58; type 2 diabetes men, HR, 1.64; 95% CI, 1.46-1.85). Unemployment HRs were higher among males with type 1 diabetes (1.25; 95% CI, 1.01-1.53) and both sexes with type 2 diabetes (women, 1.09; 95% CI, 1.03-1.16; men, 1.17; 95% CI, 1.08-1.27). Between the sexes, both diabetes cohorts had higher HRs of disability pension (type 1 diabetes women, HR, 1.90; 95% CI, 1.46-2.46; type 2 diabetes men, HR, 2.09; 95% CI, 1.38-3.18 vs. type 2 diabetes women, HR, 1.78; 95% CI, 1.62-1.96; type 2 diabetes men, HR, 2.11; 95% CI, 1.86-2.40). Women with type 2 diabetes were the only patients less likely to return to work from sickness absence (HR, 0.91; 95% CI, 0.86-0.98) or unemployment (HR, 0.89; 95% CI, 0.85-0.94). HRs for diabetes in terms of unemployment, sickness absence while unemployed, and disability pension were much higher for men compared with women. The study authors called for future research to take into account comorbidity and social gradient.

Read the original post:
The Effect of Diabetes on the Labor Market - DocWire News

Read More...

The Effect of Adding Medications to Type 2 Diabetes Regimen on Adherence in Adolescents – DocWire News

Thursday, December 12th, 2019

Studies have evaluated the adverse impacts of non-adherence to medication among adults with type 2 diabetes, including poor outcomes and increased healthcare costs. However, data are limited on adolescent patients. The Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study examined whether additional oral medications or insulin impacted adherence to primary study medication. The TODAY study included 699 patients aged 10 to 17 years who were recently diagnosed with type 2 diabetes. Patients were classified as adherent (80% taken by pill count) or non-adherent (<80%); adherence rates were compared by patients who did and did not have additional medications. At 36 months, just less than half of patients (46.3%) were taking additional oral medications, and 31.9% were on insulin. Study medication adherence did not differ with additional oral medications: zero additional medications prescribed, 55.1%; one, 67.1%; and two or more, 56.7% (P=0.16). Female patients taking oral contraceptives had higher 36-month adherence (65.2% vs. 55.8%; P=0.0054), and patients on insulin had lower 36-month adherence (39.7% vs. 59.3%; P<0.0001). Patients with depression at baseline had lower adherence (P=0.008). The researchers called for future studies to explore potentially modifiable risk factors associated with medication adherence.

Read more:
The Effect of Adding Medications to Type 2 Diabetes Regimen on Adherence in Adolescents - DocWire News

Read More...

People Living With Type 2 Diabetes Want Information and Empathy From Their Doctors More Than New Medications – BioSpace

Wednesday, December 11th, 2019

SAN FRANCISCO, Dec. 10, 2019 /PRNewswire/ --MyHealthTeams, creator of the largest and fastest-growing social networks for people facing chronic health conditions, today unveiled new research conducted among the more than 100,000 registered members of DiabetesTeam, the social network for people living with Type 2 Diabetes. A majority (59%) of those surveyed report they are either not satisfied or only somewhat satisfied with their current treatment. Yet when asked what they most want from their doctor, only 6% said "new treatments." More than 7 times as many respondents prioritized wanting their endocrinologist to provide "more information" on recommended lifestyle changes (22%) and "listening and understanding" about the challenges of managing their diabetes (21%).

The issue is not a lack of understanding about the importance of lifestyle changes. The gap is in getting practical tips for successfully adopting lifestyle changes -- especially in the context of dealing with the wide-ranging impact diabetes has on daily life. MyHealthTeams identified two key areas in which people living with diabetes know they want to improve - but aren't sure what to do or how to start:

Quality of Life Impact

Beyond high blood sugar, people with Type 2 Diabetes report experiencing a wide range of symptoms of the disease in the past year, including:

The impact of diabetes on daily life is significant, with survey respondents reporting top challenges including:

"What's clear is that managing blood sugar is just one piece of the diabetes puzzle, and people living with this condition are juggling a lot," said Eric Peacock, cofounder and CEO of MyHealthTeams. "The call to action across the healthcare ecosystem is to empower consumers with information and support to act as their own health advocates within this context. People need practical advice and emotional empathy. It's about much more than medicine."

This research was conducted among the more than 100,000 registered members of DiabetesTeam. 478 individuals responded to the online survey. Full survey findings are available at https://www.diabetesteam.com/resources/the-results-are-in-what-people-with-type-2-diabetes-want-most-from-their-doctors-is-information-not-new-treatments.

About MyHealthTeamsMyHealthTeamsbelieves that if you are diagnosed with a chronic condition, it should be easy to find and connect with others like you. MyHealthTeams creates social networks for people living with a chronic health condition. Millions of people have joined one of the company's 34 highly engaged communities focusing on the following conditions: Crohn's and colitis, multiple sclerosis, lupus, fibromyalgia, pulmonary hypertension, spondylitis, eczema, myeloma, hyperhidrosis, rheumatoid arthritis, psoriasis, leukemia, lymphoma, irritable bowel syndrome, Parkinson's, Alzheimer's, epilepsy, hemophilia, hidradenitis suppurative, depression, heart disease, type 2 diabetes, osteoporosis, COPD, chronic pain, migraines, food allergies, obesity, HIV, PCOS, endometriosis, breast cancer and autism. MyHealthTeams' social networks are available in 13 countries.

View original content to download multimedia:http://www.prnewswire.com/news-releases/people-living-with-type-2-diabetes-want-information-and-empathy-from-their-doctors-more-than-new-medications-300972655.html

SOURCE MyHealthTeams

Originally posted here:
People Living With Type 2 Diabetes Want Information and Empathy From Their Doctors More Than New Medications - BioSpace

Read More...

Sanofi to restructure its Onduo, Verily partnership alongside diabetes exit – FierceBiotech

Wednesday, December 11th, 2019

As its new CEO begins to move Sanofi away from new diabetes research, the drugmakerand producer of one of the worlds top-selling insulinswill also look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.

The restructuring comes shortly after the joint venture celebrated the completion of its expansion across the continental U.S., announcing that it now offers counseling services in 49 states. In addition, Onduo recently published a promising real-world evidence study showing gains in glucose control among type 2 diabetes patients with high blood sugar.

The virtual diabetes venture was first launched in September 2016 with nearly $500 million in equal investments from the French Big Pharma and Googles life science-focused sister company Verily.

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

Now, newly installed chief Paul Hudson aims to refocus the company on its strongest products in immunology and vaccines, while discontinuing its R&D programs in diabetes and cardiovascular diseases following struggling sales. All in all, the drugmaker hopes to save 2 billion, or $2.2 billion U.S., by 2022.

RELATED: Sanofi CEO Hudson backs away from struggling diabetes, cardiovascular areas in strategy unveiling

In a capital markets day presentation to pitch its new strategy, Sanofi said it would direct its cashflow from diabetes and cardiovascular treatments to already mature markets. It would also halt the planned launch of efpeglenatide, a GLP-1 injection for Type 2 diabetes, and instead seek a partner to take over its commercialization.

Regarding Onduo, Hudson said the company over-invested in the project in the past. Sanofi will stay on as a financial backer, but wont be involved in its ongoing operations, according to reports.

RELATED: Sanofi, Verily and Sensile to build all-in-one insulin patch pump

Whether this means more independence for Onduo remains to be seen. In late November, the virtual clinic amended its collaboration and license agreement with diabetes hardware maker Dexcom, making it the ventures preferred supplier of continuous glucose monitoring devices for its Type 2 diabetes program.

In return, Dexcom inked a $250 million upfront payment in shares of common stock, and signed on to additional payments of $280 million linked to future product launches and sales milestones. In addition, Dexcom and Verily expanded their collaboration options for new products and software, including programs for Dexcoms CGM systems.

Onduos smartphone-based clinic officially launched in early 2018, which aims to connect patients with its own network of board-certified endocrinologists to guide lifestyle and medication changes and track potential long-term complications of diabetes.

Last week, Onduo published real-world data gathered from 740 of its participants, showing that 92% of those with the highest starting HbA1c saw decreases of 2.3 percentage points through the telehealth programfrom an average of 10.7% down to 8.3%.

The data was taken from users from 21 U.S. states, with 30% living in rural communities. Nearly half of the participants were remotely prescribed and shipped CGMs during the study, according to Onduo. The results were published in the Journal of Diabetes Science and Technology.

Read more from the original source:
Sanofi to restructure its Onduo, Verily partnership alongside diabetes exit - FierceBiotech

Read More...

85-year-old man with Type 1 diabetes shatters expectations – WNDU-TV

Wednesday, December 11th, 2019

There are more than a million people who have Type 1 diabetes, and they're expected to live at least 10 years less than Americans without it.

In fact, there are only 90 diabetics who have lived more than 70 years.

But one man crushed that goal 15 years ago and is telling others how they can do it too.

Eighty-five-year-old Don Ray can't remember a life without diabetes.

As a child, Don could not go to gym class. He couldn't play sports. He couldn't even play hide and seek.

"Because if you were to hide, and they can't find you and you have an insulin reaction or a hypoglycemia, you might really be in trouble because they will never find you," Don explains.

He was told he wouldn't live past his 30s. But eventually he got tired of hearing, "You can't, you can't, you can't."

"I would go to gym class when I started school in kindergarten and first grade, and I'd sit in the chair in gym class and I'd watch these kids, and I knew I could do this, cause I just knew I could do this," Don says.

Don and his dad started playing catch, and that turned into 20 years of playing football and 30 years of baseball.

And he did it because "he followed the rules," according to Betul Hatipoglu, MD, at the Cleveland Clinic.

What rules? First make sure your blood sugar is in check: between 80 and 130 milligrams. If it's too low, eat some carbs, but don't forget to check while working out.

"If they are going to exercise for an hour, they have to check it in 30 minutes again to make sure they are still in the safe zone," Hatipoglu says.

But don't take too much insulin before your meal or before your workout.

"So if you are going to exercise after lunch, for lunch you take less insulin so it is safer for you," Hatipoglu says.

And if you're working out after dinner, be careful as well. You don't want any overnight complications.

"If you take care of the disease, the disease will take care of you, and you can if you take care of yourself," Hatipoglu explains.

Nowadays, there are nearly 140,000 people diagnosed with diabetes each year in the U.S. alone. But in 30 years, an expected five million Americans will be diagnosed with Type 1 diabetes.

DIABETES TYPE 1: DON SHATTERS EXPECTATIONS! REPORT #2699

BACKGROUND: Glucose is a critical source of energy for your brain, muscles, and tissues. When you eat, your body breaks down carbohydrates into glucose and this triggers the pancreas to release a hormone called insulin. Insulin acts as a "key" that allows glucose to enter the cells from the blood. Your body can't function or perform properly if it doesn't produce enough insulin to effectively manage glucose. This is what produces the symptoms of diabetes. Uncontrolled diabetes can lead to serious complications by damaging blood vessels and organs. It also increases the risk of heart disease, stroke, kidney disease, nerve damage, and eye disease. Nutrition and exercise help manage diabetes, but it's also important to track blood glucose levels. Treatment may include taking insulin or other medications. (Source: https://www.healthline.com/health/diabetes/facts-statistics-infographic#1)

COPING WITH TYPE 1 DIABETES: People who have had type 1 diabetes for a long time may develop what's called "diabetes burnout." This can happen when you start to feel burdened by the disease. A good support system is essential to coping with type 1 diabetes. Spending time with friends and family or talking with someone you trust are ways to manage diabetes distress, which can include stress and anxiety. Taking good care of yourself can reduce diabetes stress and help you cope with the condition. Making sure to eat well, exercise, and learn how to monitor blood sugar levels are important. Getting enough sleep each night and taking time to relax and enjoy life are also very important. There are resources available to help you manage type 1 diabetes such as apps designed to count carbs, watch blood sugar levels, and track progress with diet and exercise. The more you know about your condition, the better prepared you'll be at taking care of yourself. Your doctor can also recommend books about type 1 diabetes. (Source: https://www.healthline.com/health/type-1-diabetes/living-with-type-1/how-you-can-cope#4)

NEW DISCOVERY FOR DIABETES: Matthias Hebrok, PhD, director of the UCSF diabetes center, and Gopika Nair, PhD, have discovered how to transform human stem cells into healthy, insulin producing beta cells. "We can now generate insulin-producing cells that look and act a lot like the pancreatic beta cells you and I have in our bodies. This is a critical step towards our goal of creating cells that could be transplanted into patients with diabetes," said Dr. Hebrok. For the longest time, scientists could only produce cells at an immature stage that were unable to respond to blood sugar levels and secrete insulin properly. The team discovered that mimicking the "islet" formation of cells in the pancreas helped the cells mature. These cells were then transplanted into mice and found that they were fully functional, producing insulin and responding to changes in blood sugar levels. Dr. Hebrok's team is already in collaboration with various colleagues to make these cells transplantable into patients. (Source: https://blog.cirm.ca.gov/2019/02/05/breakthrough-for-type-1-diabetes-scientist-discovers-how-to-grow-insulin-producing-cells/)

Read more here:
85-year-old man with Type 1 diabetes shatters expectations - WNDU-TV

Read More...

Mothers With Diabetes, Kids With Heart Disease – Managed Care magazine

Wednesday, December 11th, 2019

Maternal diabetes before or during pregnancy is associated with increased risks of metabolic syndromeand congenital heart disease in offspring. Research has shown that the children of mothers with elevated blood sugar that is shy of level that would categorize them as havingof gestational diabetes are, nonetheless,more likely to be obese. But less is known about the associations between prenatal exposure to maternal diabetesand early-onset CVD in infants. So researchers from Aarhus University Hospital, Denmark, and University of California, Los Angeles, looked at data from nearly 2.5 million births to find out more. They reported their results on Dec. 4, 2019, on the BMJ website,

During up to 40 years of follow-up, 1,153 offspring of mothers with diabetes were diagnosed with CVD, as were 91,311 children of mothers without diabetes. The offspring of mothers with diabetes had a 29% increased overall rate of early-onset CVD.

Children of mothers with diabetes were also more likely to have diabetes, hypertension, hypercholesterolemia, and chronic kidney diseases, and to be obese. The rates of specific types of CVD were increased for heart failure, and close to doubled for hypertensive disease, deep vein thrombosis, and pulmonary embolism. A mother with diabetes and CVD herself also nearly doubled the offsprings chances of early-onset CVD.

The diabetic intrauterine environment could have a programming effect on the development of CVD in children, the researchers say. They note that during pregnancies complicated by diabetes, large amounts of maternal glucose freely cross the placenta, which could lead to increased secretion of fetal insulin. Exposure to hyperinsulinemia and hyperglycemia could have long-lasting effects, they say, and result in changes in vascular function. Their findings underscore the importance of screening for diabetes risks, especially in pregnant women, to avoid multigenerational hits to heart health.

Original post:
Mothers With Diabetes, Kids With Heart Disease - Managed Care magazine

Read More...

Trial suggests fasting 14 hours a day helps diabetes and weight loss – New Atlas

Wednesday, December 11th, 2019

An interesting new clinical study is suggesting restricting food intake to a 10-hour window each day may be a simple yet beneficial way to help treat metabolic syndromes such as diabetes or heart disease. The 12-week pilot study revealed the eating intervention, in conjunction with prescribed medicines, improved patients health outcomes.

One of the more fascinating dietary fashions to arise in recent times is known as time-restricted eating (TRE). Instead of interspersing whole days of fasting across a week or month, this eating strategy looks to limit your caloric intake to short windows of time in a given 24-hour period. Generally, TRE methods suggest only eating between four and eight hours a day, meaning a fasting stretch of 16 to 20 hours.

One of the theories underpinning these dietary strategies is that restricting eating to a limited time window better synchronizes a persons caloric intake with their circadian rhythms. Epidemiological studies have found a majority of people spread their food intake over at least 15 hours a day. As little as 10 percent of people compress all their meals into a 12-hour-or-less stretch each day. While some research is building to suggest health benefits to only eating in four- to eight-hour windows, this new study set out to ascertain whether a 10-hour eating window could be just as beneficial.

"There has been a lot of discussion about intermittent fasting and what time window people should eat within to get the benefits of this kind of diet," explains Satchidananda Panda, co-corresponding author on the new study. "Based on what we've observed in mice, a 10-hour time window seems to convey these benefits. At the same time, it's not so restrictive that people can't follow it long-term."

To test the eating strategy on human subjects a team of researchers from the Salk Institute and the University of California, San Diego, conducted a small pilot study. They recruited 19 subjects, most classified as obese and receiving pharmacological treatment for a diagnosed metabolic condition. All subjects self-reported prior eating patterns spanning at least 14 hours a day.

The intervention tested was incredibly simple. Subjects were directed to continue regular diets and exercise but simply compress any caloric intake to a 10-hour window each day, essentially letting their bodies fast for 14 hours across every 24-hour cycle.

For such a small and simple intervention the results were somewhat impressive, with an average three to four percent reduction in body weight and body mass index seen across the entire cohort after three months. Alongside self-reported improvements to general energy levels and sleep quality, the cohort displayed reductions in cholesterol levels and blood pressure at the end of the 12-week trial.

"We told people that they could choose when they ate their meals, as long as they remained within the 10-hour window," says Panda. "We found that universally, they chose to eat breakfast later, about two hours after waking, and to eat dinner earlier, about three hours before going to bed."

The researchers behind the new study are well-aware of the numerous limitations behind such a small trial. Most notably the trial did not include a control group which makes it difficult to clearly correlate the final result with the studied eating intervention. Duane Mellor, from Aston University, points out the lack of control isnt the only problem with this particular study.

In the case of this study there are lots of limitations, not just the lack of a control group a key one being that the act of recording food intake has been shown in other studies to reduce calorie intake and help with weight loss, says Mellor, who did not work on this new study. Also, although lots of tests were done on the participants, it seems unclear how they justify the conclusion that improvements were seen independent of weight change as there simply was not a big enough number of people to make this assessment.

So, were the beneficial effects seen in this study directly related to the TRE strategy? Or were the health improvements more a reflection of the diet indirectly lowering overall caloric intake and making the cohort more aware of their eating patterns?

Its possible to over speculate that time-restricted eating is a magic bullet to health whereas it may be that its just through calorie restriction, suggests Jenna Macciochi, an immunologist from the University of Sussex. On the flip side, for people who are struggling with fad diets it may be a useful tool and help compliance.

Macciochi, who did not work on this new research, does point out the most encouraging part of the new study is that it highlights how easy this particular dietary modification can be implemented and sustained. The compliance rate for the trial was very high, with a significant number of the participants reporting continuing the dietary strategy, in some form, for up to a year. This suggests, unlike some other intermittent fasting or TRE diets, a 10-hour daily eating window is relatively easy to integrate into a persons life, and can be maintained for extended periods of time without too much trouble.

So, moving forward the next step for the researchers is to better verify the metabolic benefits of this eating plan in larger cohorts. A clinical trial is already underway in a much larger group with the hopes of understanding the physiological effects of what could essentially be called a 14:10 eating plan.

The new study was published in the journal Cell Metabolism.

Sources: Salk Institute, Cell Press

Read more here:
Trial suggests fasting 14 hours a day helps diabetes and weight loss - New Atlas

Read More...

Type 2 diabetes: Drinking this type of tea could lower your blood sugar – Express

Wednesday, December 11th, 2019

We demonstrated that black tea reduced incremental blood glucose after sucrose consumption at 60, 90 and 120 minutes compared with placebo, wrote the authors of the study.

The data confirm that polyphenols lower glycemic response and may be responsible for the lower rates of diabetes observed with tea and coffee consumption, said Peter Clifton, M.D., PhD., professor of nutrition at the University of South Australia in Adelaide, who recently conducted a review of the role of dietary polyphenols (in tea, cinnamon, coffee, chocolate, pomegranate, red wine and olive oil, among others) in regulating glucose homeostasis and insulin sensitivity, which was published in Nutrients.

Echoing the findings, a study in mice compared the effects of black and green tea extract on blood sugar levels.

Results found that they both lowered blood sugar and improved how the body metabolised sugar.

Carbs with a low GI value are more slowly digested, absorbed and metabolised and cause a lower and slower rise in blood glucose and therefore insulin levels.

to the NHS, many people have type 2 diabetes without realising because symptoms do not necessarily make you feel unwell.

Symptoms include:

You should speak to your GP if you have any of the symptoms of type 2 diabetes or you're worried you may have a higher risk of getting it, advises the health body.

It added: The earlier diabetes is diagnosed and treatment started, the better. Early treatment reduces your risk of other health problems.

Continued here:
Type 2 diabetes: Drinking this type of tea could lower your blood sugar - Express

Read More...

Harvey Weinstein’s diabetes and spine condition to blame for his appearance – Page Six

Wednesday, December 11th, 2019

Harvey Weinstein hobbled into Manhattan court Friday looking pallid and unsteady thanks to severe diabetes and a spine condition, sources told The Post.

The 67-year-old accused rapist and former powerhouse Hollywood producer who was in court for a new bail hearing has suffered from Type 2 diabetes, back issues and other health problems that have been in free-fall since his arrest, sources said.

Weinsteins health problems paved the way for him to be allowed to wear a modified monitoring device while hes out on bail awaiting trial on sex charges and the gadget was at the heart of Fridays hearing.

Weinstein who had a handler help prop him up as he entered the courtroom was originally outfitted with a regular ankle bracelet, but because of his health issues, bail bondsman Ira Judelson swapped it out for a two-part device. The new device includes a slimmer ankle bracelet with a separate signaling component. The original device is not prone to the same user error.

The one-piece device was problematic for his leg and medical issues, Weinsteins lawyer, Donna Rotunno, told the court of the original, much bulkier monitor.

But Assistant DA Joan Illuzzi-Orbon said Weinsteins ankle monitor was untraceable on at least 56 separate occasions, in violation of his bail conditions. Prosecutors said Weinstein repeatedly failed to keep within range as required.

Due to the violations and new bail reform laws taking effect next year, Weinsteins bail package has to be re-examined, with both sides making their arguments Friday. Justice James Burke is set to rule on the issue Wednesday.

Weinstein is currently free on $1 million cash bail. He faces up to life in prison on charges of predatory sexual assault, criminal sex act and rape in connection with three accusers.

Matthew McDermott

Read this article:
Harvey Weinstein's diabetes and spine condition to blame for his appearance - Page Six

Read More...

How worms revealed a key protein in insulin synthesis and diabetes – FierceBiotech

Wednesday, December 11th, 2019

By studying the nematode Caenorhabditis elegans, scientists from Vanderbilt University and the University of Michigan have identified a protein that's key for insulin synthesis, the understanding of which they say could lead to new approaches to prevent and treat Type 2 diabetes.

The protein, called TRAP-alpha, is widely shared across worms, flies and mammals, including humans. In a study published in the journal Science Advances, the team showed that TRAP-alpha is required for insulin production, corroborating previous knowledge that alterations in the TRAP-alpha gene are linked to the development of diabetes.

The researchers made the discovery while screening for genetic clues to the PI3K/Akt signaling pathway that may contribute to reduced insulin signaling. Irregularities in the PI3K/Akt pathway have been linked to many human diseases, including cancer, cardiovascular disease anddiabetes.

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

The screens turned up TRAP-alpha. The protein is part of a complex known as translocon that helps moveor translocatenewly synthesized proteins into the endoplasmic reticulum (ER) of cells for further processing before theyre eventually secreted.

The researchers discovered that deletingthe C. elegans equivalent of TRAP-alpha affects the worms' insulin signaling pathway.

They went on to delete TRAP-alpha in insulin-making pancreatic beta cells of rats. Doing so led to a sharp decline in total insulin, the team found. Preproinsulin, the precursor molecule to insulin, was not properly transferred into the ER for final processing, so most of it was degraded.

TRAP-alpha was not on anyone's radar in terms of being required for insulin biogenesis, Patrick Hu, the studys senior author, said in a statement. Our work highlights the value of using a model organism likeC. elegansto do an unbiased genetic screen. It led us to a molecule that seems to be important in making insulin and that could very well shed light on the pathogenesis of diabetes, a common disease that affects about 10% of the U.S. population.

RELATED:Subtle chemical shift reverses prediabetes in Merck-partnered mouse trial

Given the prevalence of diabetes, several research groups are also working on new ways to tackle it. Scientists from the University of Utah, in collaboration with Merck Research Laboratories, recently prevented or reversed prediabetes in mice. They did it by shutting down an enzyme called DES1 to reduce the amount of fatty lipid ceramides, which is key in metabolic health.

A team at the University of Geneva treated Type 1 diabetes in mice byconverting non-insulin-producing alpha and gamma endocrine cells into beta cells with the help of two transcription factors, PDX1 and MafA.

Understanding TRAP-alpha could inspire new ideas to prevent or treat Type 2 diabetesand maybe even more diseases, Hu and colleagues argued.

In the current study, the researchers noticed TRAP-alpha plays a role in promoting ER homeostasis, or the balance between incoming proteins and ER the proteins that help fold them. Loss of TRAP-alpha may cause ER stress, which can lead to cell death, the team reported.

Preproinsulin is the first client protein for TRAP-alpha to deliver into the ER for processing, and the scientists hope to find more like it.

It's likely other secreted molecules besides insulin might be affected by TRAP-alpha deletion, Hu said in a statement. If we can understand the broader role that TRAP-alpha is playing in maintaining protein homeostasis, we might develop new ways to approach other diseases, too.

More:
How worms revealed a key protein in insulin synthesis and diabetes - FierceBiotech

Read More...

Diabetes treatment to cost less on cheaper version – Times of India

Wednesday, December 11th, 2019

MUMBAI: There is some good news for the over 72 million diabetics in India, with a cheaper version of a blockbuster drug hitting the market on December 10. The domestic pharmaceutical market is abuzz with news of over 15-20 companies launching generic versions of the widely-prescribed anti-diabetic drug Vildagliptin, with its price expected to crash by half.

The potential of more affordable diabetic care comes in the wake of Swiss major Novartis-owned Vildagliptin losing patent on Monday a development closely watched for months. Dozens of companies have readied plans to get a slice of the action in the growing Rs 14,000-crore diabetes therapy market, with the number of players expected to cross 50 soon.

With the drugs patent expiry, the price may drop to Rs 6 per tablet over the next few months, from the existing Rs 20-25 each. What makes the patent expiry significant for Indian pharma is that Vildagliptin is the first among the gliptins, a relatively new class of oral diabetes drugs, to get off the block, and also the first diabetes medicine whose end of patent life is being seen by industry. Vildagliptin is a part of a class of diabetes medications called dipeptidyl peptidase IV or DPP4 inhibitors.

The innovator brand Galvus (along with combination of Metformin) cornered around Rs 600 crore, a lions share of total Vildagliptin market of Rs 950 crore (moving annual total (MAT) November 2019). The company also has agreements with USV, Cipla and Abbott, with their brands Jalra, Vysov and Zomelis respectively available in 50mg Vildagliptin, and in combination with Metformin.

Days before the launch, the market started hotting up with Mumbai-based Eris Lifesciences acquiring Zomelis from Novartis for around Rs 100 crore, and USV reportedly being in talks to acquire Jalra. When contacted, a Novartis spokesperson said, When patents expire, high-quality generics help lower the overall cost of healthcare and improve access to medicines for societies around the world, in a circle of discovery, development, commercialisation and loss of market exclusivity. We will continue to serve people living with diabetes through the innovator molecule in India, Galvus.

Read the original post:
Diabetes treatment to cost less on cheaper version - Times of India

Read More...

Message to young women with diabetes: Marriage and children, you can have it all! – Times of India

Wednesday, December 11th, 2019

In the last 21 years, I have been working closely with young women who have type 1 or type 2 diabetes and many of them have voiced a persistent concern and fear: will they be able to lead a fulfilling life as wives and mothers. They seem to have received little or no reassurance from family and friends. Social discrimination, misconceptions and stigma are still creating psychological and emotional problems for these young women.Research shows that societal stigma, shaming or discrimination of people with diabetes has a negative impact on patient self-care and leads to poor treatment outcomes.[i] Women face much more of this than men. They are deemed unfit for marriage and motherhood. They face this stigma on all fronts: from their own family, extended relatives, colleagues at work and from prospective spouses and their families.I would like to clear some of these misconceptions and send out a message of hope and reassurance to these young women.Never assume, always ask the doctorLack of understanding is the source of this stigma, both in rural and urban India. Poor understanding of the disease at all levels - patients, families, prospective in-laws, co-workers - creates a web of fear about the disease, its risks and its impact on everyday living. So many families assume no one wants to wed their daughter, because she has a lifelong chronic condition. They also assume that the young woman will be unable to bear children, and if she does, the child will be at risk of developing diabetes at some point in life.

In light of this, it becomes the doctors responsibility to guide patients and their families, give them the information they need on general diabetes management and particularly on pre and post-natal diabetes care. Patients need to be told that while diabetes does increase the risk of certain complications, advancements in medicine and technology have made these well manageable today.

Do not hide your condition, and never neglect your medicationI have met several young women patients in the process of finding a marriage partner, struggling with the dilemma of whether to tell their prospective partners and families about their diabetes status. Many have reported that when they did open up about their condition soon after marriage, they were advised to seek alternative medical treatment by their husbands and in-laws and asked to give up insulin therapy! Hiding the fact that they have diabetes has also led to an erratic medication schedule leading to horrifying results. Many patients developed a condition called ketoacidosis (excess blood acids called ketones) and needed to be rushed to the emergency room.

One of my biggest concerns is that newly diagnosed patients sometimes keep their diabetes status a secret from even their immediate family and colleagues for fear of judgement. Some of my new patients admit to taking their insulin or checking their blood sugar only in the privacy of their washroom, and do not do so as often as recommended if they are in a public place.

My message to patients here is simple: no person and no circumstance must ever trump your own health. Neglecting to monitor your blood sugar or to take your medication as prescribed, can put you at high risk of many complications, some of which are life threatening. Patients on insulin therapy should ask their doctor to help pick an insulin type that suits their daily schedule and body requirements.

Read the original:
Message to young women with diabetes: Marriage and children, you can have it all! - Times of India

Read More...

She invented a product to help those with Type 1 diabetes, and she’s featured in a new book – East Idaho News

Wednesday, December 11th, 2019

Laurel Bloomfield of Rigby is a contributing author for a new book targeted to entrepreneurs. | Courtesy photos

RIGBY Laurel Bloomfield of Rigby is an entrepreneur, inventor, mother and wife, and she will soon add author to her list of accomplishments.

She is one of 71 authors who will be featured in Air Fryer Secrets. Its not a cookbook rather, its an anthology providing business-building tips and strategies. Each chapter was written by a different author and caters to a specific niche in the marketing and entrepreneurial space.

Everything you would need to start an online business today is covered in the book, Bloomfield tells EastIdahoNews.com.

Bloomfields contribution is a chapter about intellectual property and how a product developer can write their own patent. She co-created a product with Nicholle Peterson and Katie Larsen several years ago designed to help those with Type 1 diabetes who wear an insulin pump. Its a pocket thats placed in the lining of clothing to hide it from view and keep it safe from damage.

RELATED | Local moms design a trendy way to carry insulin pumps

If you send a 5-year-old kid to school with a $10,000 pump, and they try to use the bathroom, it could fall in the toilet. Other kids have cut the tubing thats hanging out of their shirt going from the pump to the infusion site. That can be a life-threatening situation, Bloomfield says.

Her pocket helps keep that device safely up against their body and holds all the tubing in place to avoid all risks of danger. The pocket also gives kids a way to hide their condition so they do not become a spectacle to people around them, she says.

I think thats important for kids dealing with Type 1 diabetes. Sometimes theyre expected to be the spokesperson for this huge disease just because they have this noticeable thing (on their body). The pocket allows them to just be kids, says Bloomfield.

Bloomfields pocket concept gained a lot of traction from some of the leading insulin pump manufacturers in the world. It was put on the market about three years ago once her fully-issued patent was approved. Today, its sold online and in stores under the name Pocket Innerware.

Boise resident Kevin Quinn, the lead author of Air Fryer Secrets, has worked with Bloomfield on numerous development projects. Hes a software developer and a partner at a CBD company, among other things. He invited her to share her expertise with readers for this book.

The inspiration for the book came from a series of live Facebook videos Quinn began posting about eight months ago.

I wanted to show folks what I could cook in the air fryer one Friday. It was funny. People tuned in and had some fun with it. Then it started to grow and people started to ask What are you cooking for Fryer Friday?' Quinn says.

The initial post was intended as a joke, but it quickly went viral and eventually became a weekly bit called Fryer Friday.

The videos have since become a Facebook engagement tool to help build an audience for many of his business projects. The title of the book is a play on words intended to convey its central message of putting yourself out there to build brand awareness.

You need to decide who your audience is that you want to sell to, and then find a unique way to sell to them, Quinn says. This book will give them so many ideas (on) how to do that.

Bloomfield and Quinn recently launched a business together called Launch Incubator, which helps entrepreneurs find an audience for their product.

Bloomfield says she is excited to be able to offer marketing strategies and other resources for current and prospective business owners.

Its kind of like a digital marketing Bible. Its something that, when I got into this space 18 months ago, I wish I wouldve known more about, Quinn says.

Air Fryer Secrets will be available to buy through Amazon on Dec. 19. Visit the website to learn more.

Continue reading here:
She invented a product to help those with Type 1 diabetes, and she's featured in a new book - East Idaho News

Read More...

Page 36«..1020..35363738..5060..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick